TLSI
TriSalus Life Sciences Inc

280
Mkt Cap
$374.73M
Volume
83,964.00
52W High
$7.70
52W Low
$3.42
PE Ratio
-3.72
TLSI Fundamentals
Price
$7.34
Prev Close
$7.50
Open
$7.56
50D MA
$5.22
Beta
0.39
Avg. Volume
133,434.37
EPS (Annual)
-$1.31
P/B
-14.00
Rev/Employee
$267,554.54
Loading...
Loading...
News
all
press releases
TriSalus Life Sciences to Host Virtual KOL Event to Discuss the TriNav Infusion System for the Treatment of Symptomatic Thyroid Disease on December 15, 2025
TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (TriSalus or the Company), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients...
Business Wire·8d ago
News Placeholder
More News
News Placeholder
TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Given Average Rating of "Moderate Buy" by Brokerages
TriSalus Life Sciences, Inc. (NASDAQ:TLSI - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the five analysts that are currently covering the company, MarketBeat...
MarketBeat·8d ago
News Placeholder
TriSalus Life Sciences (NASDAQ:TLSI) Upgraded by Wall Street Zen to Hold Rating
Wall Street Zen upgraded TriSalus Life Sciences from a "sell" rating to a "hold" rating in a research report on Friday...
MarketBeat·14d ago
News Placeholder
FY2026 EPS Estimates for TLSI Increased by Cantor Fitzgerald
TriSalus Life Sciences, Inc. (NASDAQ:TLSI - Free Report) - Equities researchers at Cantor Fitzgerald boosted their FY2026 earnings estimates for shares of TriSalus Life Sciences in a research note...
MarketBeat·22d ago
News Placeholder
TriSalus Life Sciences Launches TriNav XP Infusion System to Expand Options for Pressure-Enabled Drug Delivery
TriSalus Life Sciences, an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients with solid tumors, is pleased to announce the...
Business Wire·24d ago
News Placeholder
TriSalus Life Sciences (NASDAQ:TLSI) Issues Earnings Results
TriSalus Life Sciences (NASDAQ:TLSI - Get Free Report) announced its earnings results on Thursday. The company reported ($0.96) earnings per share for the quarter, missing analysts' consensus...
MarketBeat·27d ago
News Placeholder
TriSalus Life Sciences, Inc. (TLSI) Reports Q3 Loss, Tops Revenue Estimates
TriSalus Life Sciences, Inc. (TLSI) delivered earnings and revenue surprises of -464.71% and +0.79%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·29d ago
News Placeholder
TriSalus Life Sciences Reports Third Quarter 2025 Results and Reaffirms 2025 Revenue Guidance
TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the Company), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to...
Business Wire·29d ago
News Placeholder
Rockwell Medical (RMTI) Reports Q3 Loss, Lags Revenue Estimates
Rockwell Medical (RMTI) delivered earnings and revenue surprises of -25.00% and -5.20%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
TriSalus Life Sciences to Participate in Upcoming Investor Conferences
TriSalus Life Sciences Inc. (Nasdaq: TLSI) (TriSalus or the Company), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients...
Business Wire·1mo ago

Latest TLSI News

View

Advertisement|Remove ads.

Advertisement|Remove ads.